| Overview |
| bs-20781R |
| CD19 Polyclonal Antibody |
| WB, ELISA, FCM, IHC-P, IHC-F, IF(ICC), IF |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD19 |
| 121-200/556 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20¡C for 12 months. |
| Target |
| 930 |
| P15391 |
| Antibody deficiency due to defect in CD19, included; AW495831; B lymphocyte antigen CD19; B lymphocyte surface antigen B4; B4; CD 19; CD19 antigen; CD19 molecule; Cd19 protein; Differentiation Antigen CD19; Leu 12; Leu12; Lymphocyte Surface Antigen; MGC109570; MGC12802; T-cell surface antigen Leu-12.ÊÊ |
| CD19 is a transmembrane glycoprotein that is delectively expressed on the cell surface of B-lymphocytes,where it activates intracellular signaling cascades involving both Ras and phosphatidylinositol 3-kinase pathways.Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.Ê |
| Application Dilution |
| WB |
|
| ELISA |
1:500-1000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(ICC) |
1:50-200 |
| IF |
|
Powered by Bioz